Details for Patent: 9,101,615

Which drugs does patent 9,101,615 protect, and when does it expire?

Patent 9,101,615 protects VARUBI and is included in one NDA.

This patent has twenty-five patent family members in thirteen countries.

Summary for Patent: 9,101,615

Title:	Intravenous formulations of neurokinin-1 antagonists
Abstract:	Pharmaceutical compositions for intravenous administration comprising the compound of Formula I ##STR00001## or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein.
Inventor(s):	Wan; Jiansheng (Warren, NJ), Gupta; Pranav (Short Hills, NJ), Monteith; David (Pittstown, NJ), Bhattacharya; Soumendu (East Windsor, NJ)
Assignee:	OPKO Health, Inc. (Miami, FL)
Application Number:	12/855,889
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 9,101,615

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tersera	VARUBI	rolapitant hydrochloride	EMULSION;INTRAVENOUS	208399-001	Oct 25, 2017		DISCN	Yes	No						PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

International Family Members for US Patent 9,101,615

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010282483
Brazil	112012003263
Canada	2770403